LipimetiX is focussed on the
cost-efficient development of its
technology through a virtual company structure under the leadership of experienced scientists and biotech business executives, through a partnership between




The Apo E mimetic Technology addresses serious unmet needs in large patient populations:

• patients with genetically based refractory hyperlipidemias who develop cardiovascular disease early in life, often due to an inability to remove cholesterol rich lipoproteins from the blood.

The novel Apo E mimetics restore the natural pathway missing in these patients.

• patients with cardiovascular disease expressed as acute coronary syndrome. The rapid cholesterol lowering and lesion regression mediated by the Apo E mimetics directly benefits the artery wall.

LipimetiX plans to develop the technology through Phase 2 proof of concept studies and then transfer the technology to a corporate partner to complete the development and commercialization.

Benu BioPharma
          and

Capstone Therapeutics.

LipimetiX Development, LLC.